231 related articles for article (PubMed ID: 23319869)
1. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes.
Gallwitz B
Diabetes Metab Syndr Obes; 2013; 6():1-9. PubMed ID: 23319869
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.
Gallwitz B
Ther Adv Endocrinol Metab; 2013 Jun; 4(3):95-105. PubMed ID: 23730503
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.
Gallwitz B
Ther Clin Risk Manag; 2015; 11():799-805. PubMed ID: 25999728
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.
Gallwitz B
Clin Med Insights Endocrinol Diabetes; 2012; 5():1-11. PubMed ID: 22879795
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Grunberger G
Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin as add-on therapy for type 2 diabetes - an overview.
Brown DX; Choudhury M; Evans M
Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
Gilbert MP; Pratley RE
Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
[TBL] [Abstract][Full Text] [Related]
11. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
Darsalia V; Ortsäter H; Olverling A; Darlöf E; Wolbert P; Nyström T; Klein T; Sjöholm Å; Patrone C
Diabetes; 2013 Apr; 62(4):1289-96. PubMed ID: 23209191
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
13. [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2012 Feb; 67(2):91-7. PubMed ID: 22482239
[TBL] [Abstract][Full Text] [Related]
14. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Singh AK; Jatwa R; Purohit A; Ram H
J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Deeks ED
Drugs; 2012 Sep; 72(13):1793-824. PubMed ID: 22913735
[TBL] [Abstract][Full Text] [Related]
17. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
Gallwitz B
Diabetes Metab Syndr Obes; 2010 May; 3():117-24. PubMed ID: 21437082
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
19. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Golightly LK; Drayna CC; McDermott MT
Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea.
Aronson R
Expert Opin Pharmacother; 2012 Jul; 13(10):1535-9. PubMed ID: 22587735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]